SAMUEL AITCHISON: Open Payments
NPI 1750949368 · EL DORADO, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,005 in 102 payments from 24 companies in 2025. Trend: 2023 $1,094 · 2024 $1,136 · 2025 $2,005
Food & beverage: $2,005
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 17 | $526 |
| GlaxoSmithKline, LLC. | 11 | $204 |
| ABBVIE INC. | 16 | $199 |
| Novo Nordisk Inc | 12 | $193 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $118 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $81 |
| Lilly USA, LLC | 4 | $68 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $65 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| Insulet Corporation | 3 | $47 |
Products named: FARXIGA, BREZTRI, QULIPTA, CAPLYTA, TRELEGY ELLIPTA, Wegovy, AIRSUPRA, XIFAXAN.
Industry payments across KS — which companies pay providers there.
